HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might
minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after …

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

The HIV-1 reservoir is the major hurdle to a cure. We here evaluate viral and host
characteristics associated with reservoir size and long-term dynamics in 1,057 individuals …

Objectives: Therapies to achieve sustained antiretroviral therapy-free HIV remission will
require validation in analytic treatment interruption (ATI) trials. Identifying biomarkers that …

Background Quantifying latently infected cells is critical to evaluate the efficacy of
therapeutic strategies aimed at reducing the size of the long-lived viral reservoir, but the low …

Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research,
seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) …

HIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its
kinetics in early acute HIV infection (AHI) is poorly understood. We longitudinally measured …

Background Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent
reservoir of latently infected cells. Approaches that force HIV transcription from these cells …